Danaher Corporation Plans Quarterly Dividend of $0.40 (NYSE:DHR)

Danaher Corporation (NYSE:DHR) announced a quarterly dividend on Tuesday, September 15th. Shareholders of record on Wednesday, September 30th will be given a dividend of 0.40 per share by the conglomerate on Friday, October 30th. This represents a c) dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Wednesday, September 30th.

Danaher has increased its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 2 consecutive years. Danaher has a dividend payout ratio of 18.7% indicating that its dividend is sufficiently covered by earnings. Analysts expect Danaher to earn $9.26 per share next year, which means the company should continue to be able to cover its $1.60 annual dividend with an expected future payout ratio of 17.3%.

Danaher Stock Performance

Shares of DHR opened at $209.23 on Wednesday. The firm has a market cap of $147.09 billion, a PE ratio of 37.16, a PEG ratio of 2.53 and a beta of 0.78. The stock’s fifty day moving average price is $203.15 and its two-hundred day moving average price is $191.90. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.77 EPS. On average, equities research analysts forecast that Danaher will post 8.53 EPS for the current year.

Danaher Company Profile

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.